Biotechnology News

$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year...

Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics...

ORLANDO, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Codetta Bio™, a leader in multi-omic solutions that combine ultrasensitive protein quantification with simultaneous RNA and DNA analysis, today...

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2...

PARIS et CAMBRIDGE, Mass., 25 févr. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement...

PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of...

Surrozen to Present at Upcoming Healthcare Investor Conference

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and...